Search

Your search keyword '"Leebeek, Frank W.G."' showing total 534 results

Search Constraints

Start Over You searched for: Author "Leebeek, Frank W.G." Remove constraint Author: "Leebeek, Frank W.G."
534 results on '"Leebeek, Frank W.G."'

Search Results

2. Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model

4. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders

5. Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)

6. A multitrait genetic study of hemostatic factors and hemorrhagic transformation after stroke treatment

9. Genetic variants, thrombocytopenia, and clinical phenotype of type 2B von Willebrand disease: a median 16-year follow-up study

13. Colorectal cancer screening in patients with inherited bleeding disorders: high cancer detection rate in hemophilia patients

14. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

18. Desmopressin response depends on the presence and type of genetic variants in patients with type 1 and type 2 von Willebrand disease

19. SYMPHONY consortium: Orchestrating personalized treatment for patients with bleeding disorders

20. The bleeding phenotype in people with nonsevere hemophilia

22. Multi‐phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations

23. Joint status of patients with nonsevere hemophilia A

24. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study

26. COVID-19 vaccination in patients with immune thrombocytopenia

28. Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature

29. Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study

30. Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands

31. Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019

32. Treatment‐related risk factors for inhibitor development in non‐severe hemophilia A after 50 cumulative exposure days: A case‐control study

33. Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

35. Illustrated State‐of‐the‐Art Capsules of the ISTH 2021 Congress

36. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial

39. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018

40. Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders

41. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease

43. Peri-operative desmopressin combined with pharmacokinetic-guided factor VIII concentrate in non-severe haemophilia A patients

44. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders

45. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

46. Psychometrics of patient-reported outcomes measurement information system in von Willebrand disease, inherited platelet function disorders, and rare bleeding disorders

47. Desmopressin to prevent and treat bleeding in pregnant women with an inherited bleeding disorder:a systematic literature review

48. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B

49. Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants:Results from the phase III HOPE-B trial 2 years after gene therapy

50. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A

Catalog

Books, media, physical & digital resources